A global consensus published in The Lancet this month proposed renaming polycystic ovary syndrome to Polyendocrine Metabolic Ovarian Syndrome, or PMOS. For a condition affecting one in eight women, this is a development worth understanding properly.
Why is the name changing?
Pathological ovarian cysts are not actually a defining feature of the condition. What the research consistently shows is a broader cluster of hormonal and metabolic disruptions that a single-organ name was never well-equipped to describe. Up to 70% of people with the condition remain undiagnosed, and knowledge gaps among both patients and clinicians are well documented.
What does the condition actually involve?
The clinical picture varies considerably between individuals. Symptoms can include irregular or absent menstrual cycles, hirsutism (excess hair growth on the face and body), acne, alopecia (hair thinning or loss), skin tags, weight changes, depression, and fertility challenges.
On investigation, findings often include elevated testosterone, high insulin levels, insulin resistance (where the body’s cells stop responding to insulin effectively), increased LH (luteinizing hormone, which triggers ovulation), and reduced SHBG (sex hormone binding globulin, a protein that binds to testosterone and keeps it inactive in the bloodstream). Because insulin suppresses SHBG, this creates a cascade effect that increases free testosterone in circulation, which drives many of the androgenic symptoms people experience such as acne, hair growth, and hair loss.
This hormonal and metabolic interconnection is precisely why the proposed name change matters. The condition is not simply ovarian.
What does the new name capture?
PMOS reflects the condition’s actual pathophysiology. Polyendocrine acknowledges the involvement of multiple hormonal systems simultaneously. The word "Metabolic" recognizes that insulin resistance is present in approximately 85% of affected individuals and that cardiometabolic risk (the combined risk to heart and metabolic health) is a core feature of the condition. Ovarian remains because ovarian dysfunction continues to be clinically significant.
What are some of the considerations for managing PMOS?
Because the condition involves intersecting hormonal and metabolic pathways, management typically addresses multiple systems. Lifestyle factors including diet, exercise, and stress regulation are the foundation. Optimizing progesterone (a hormone that supports menstrual regularity and counterbalances estrogen) and addressing insulin resistance are common hormonal priorities.
Metformin is a frequently used prescription option, working by reducing insulin levels, which in turn raises SHBG and reduces free testosterone. This targets the hormonal cascade at a metabolic level.
Other common treatments include the combined oral contraceptive pills, which regulate cycle hormones and reduce androgen-driven symptoms like acne and irregular periods, and spironolactone, which blocks testosterone at the receptor level to manage hirsutism and acne.
Why This Matters to US
At The Pharmacy Lab, we think this conversation matters. Language shapes how conditions are understood, communicated, and managed. For something that affects so many people, getting the name right feels important. If any of this has raised questions about your own health or you are not sure where to start, please reach out. We are always happy to help.
Sources:
Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., Piltonen, T., & Global Name Change Consortium (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet (London, England), S0140-6736(26)00717-8. Advance online publication. https://doi.org/10.1016/S0140-6736(26)00717-8
